Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.

摘要: Abstract Background Vaccines are now available for the prevention of HPV-16/18-related cervical infections and pre-cancers, primarily targeting adolescent girls. Since risk HPV exposure potentially persists throughout a woman's sexual life, vaccine-derived immunity should be long-term. The current study, HPV-024 ( NCT00546078 , http://clinicaltrials.gov ), assessed immune memory in North American women who received three doses HPV-16/18 AS04-adjuvanted vaccine 7 years earlier HPV-001 NCT00689741 ). Methods Women vaccinated 4th-dose (024-4DV group, N  = 65). Post responses were compared with post 1st-dose cross-vaccination controls (024-3DV  = 50). Reactogenicity was between administration. Results Pre 4th-dose, 100% subjects 024-4DV group remained seropositive anti-HPV-16/18 antibodies (ELISA). Compared to pre GMTs anti-HPV-16 anti-HPV-18 respectively 9.3-fold 8.7-fold higher at day 7, 22.7-fold 17.2-fold month 1. 1st-dose, 80.5-fold 205.4-fold 11.8-fold 20.5-fold Furthermore, 68.2% 77.3% had specific B-cells, respectively, rising one vaccination. generally well tolerated. Conclusion A triggered rapid strong anamnestic response previously women, demonstrating vaccine-induced memory.